ASCO GU 2023: Nivolumab plus Cabozantinib vs Sunitinib for First-Line Treatment of Advanced RCC: 3-Year Follow-up from the Phase 3 CheckMate 9ER Trial urotoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from urotoday.com Daily Mail and Mail on Sunday newspapers.
In the absence of head-to-head trials, the findings help validate the applicability of phase 3 results to routine care. The study was published as a preprint and has not yet been peer reviewed.